LL-37

LL‑37 is a human cathelicidin antimicrobial peptide that also promotes wound healing and modulates immune responses; users typically take it off‑label for those properties. In the community the most common regimen is generally about 200 µg daily, in practice, with reported doses ranging from 25 µg up to 10 mg, and timing or cycling not usually specified. The main limitation is that the off‑label evidence base is thin, with exploratory indications lacking posted results, and injection‑site reactions have not emerged as a consistent theme.

Half-life~1 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsno dataAnecdotalEfficacyAnecdotalSideEffectsPrice2.01.73.03.12.0

Measured on 5 of 6 axes

Research Evidence

Evidence shape

LL-37 currently holds a low evidence tier, as human research is restricted to three small-scale diagnostic and mechanistic studies. While a single trial exists for diabetic foot ulcers, the broader clinical landscape remains thin, with no completed trials to support therapeutic efficacy. The existing data is largely exploratory or confined to preclinical research, leaving the peptide without the robust, multi-trial validation required to establish standard clinical use.

Depthhow much
1 registered trial
Breadthhow many areas
3 indications mapped
2 thin / exploratory · 1 animal-only · 1 single-trial long-tail
Qualityhow rigorous
No completed trials
1 linked publication on registered trials
Breadth and depth18 rows captured
Human
direct clinical signal
4
Animal
translational support
9
In vitro
mechanistic support
5
HighMediumLow

Anecdotal efficacy

LL-37 side effects

Clinical research side effects

Clinical safety table not projected yet.

Anecdotal side effects

Price

Full buying guide →
1
peptidesourcehub.com
--
50 mg
$149.90
$3/mg
2
Peptidescollective
US
10 mg
$42.00
$4.2/mg
3
Pepclub Usa
--
50 mg×10
$215.00
$4.3/mg
4
Allmypeptides
GB
10 mg
$43.44
$4.35/mg
5
Research Peptides Europe
Europe
10 mg
$45.71
$4.57/mg
6
Evolve BioPep
USA
5 mg
$25.00
$5/mg

price offers can be sorted by column

1-6 of 126

LL-37 dosing & protocol

How LL-37 is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet
Frequency
not reported
Route
topical

Zero completed trials have been identified for LL-37 in research trials, so dosing for this tier has not been reliably extracted.

Clinician practice
Doctor & published-protocol guidance
Typical dose
—
0
2 mg
4 mg
6 mg
8 mg
10 mg
no dose captured for this tier yet

No structured protocol details captured for this tier yet.

Anecdotal
Community-reported real-world use · n = 15
Typical dose
200 µg25 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 15 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
mostly daily
Route
subQ

Most users (7 of 15) give LL‑37 subQ daily, typically about 200 µg (reported range 100 µg–10 mg); one user doses three times weekly at 1 mg, and another 7 report doses without a set schedule, usually 500 µg. No cycling is noted.

15 sources

Related peptides

ThymalinThymosin Alpha-1ThymulinVIP